KR920019347A - 당뇨병의 치료방법 - Google Patents

당뇨병의 치료방법 Download PDF

Info

Publication number
KR920019347A
KR920019347A KR1019920005491A KR920005491A KR920019347A KR 920019347 A KR920019347 A KR 920019347A KR 1019920005491 A KR1019920005491 A KR 1019920005491A KR 920005491 A KR920005491 A KR 920005491A KR 920019347 A KR920019347 A KR 920019347A
Authority
KR
South Korea
Prior art keywords
insulin
mammal
amount
rapamycin
composition
Prior art date
Application number
KR1019920005491A
Other languages
English (en)
Other versions
KR100206054B1 (ko
Inventor
리 베더 윌리암
나스 세갈 수렌드라
무어 아담스 로렐
조셉 카지아노 토마스
Original Assignee
원본미기재
아메리칸 홈 프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 아메리칸 홈 프로덕츠 코포레이션 filed Critical 원본미기재
Publication of KR920019347A publication Critical patent/KR920019347A/ko
Application granted granted Critical
Publication of KR100206054B1 publication Critical patent/KR100206054B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

당뇨병의 치료방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 포유동물에게 유효량의 라파마이신을 경구, 비경구, 비내, 기관지내 또는 작장내 투여함을 특징으로 하여, 인슐린 의존성 진성 당뇨병의 발생을 억제시키거나 진행을 지연시킬 필요가 있는 포유동물을 치료하는 방법.
  2. 제1항에 있어서, 라파마이신을 인슐린과 배합하여 투여하는 방법.
  3. 제2항에 있어서, 정상적인 글루코스 농도를 유지시키는데 필요한 인슐린의 양이 인슐린만을 투여하여 정상적인 글루코스 농도를 유지시키는데 필요한 양 미만인 방법.
  4. 인슐린 의존성 진성 당뇨병의 악화를 억제시키거나 진행을 지연시킬 필요가 있는 포유동물을 치료하는데 사용하기 위한 라파마이신 및 약제학적으로 허용되는 담체를 포함하는 조성물.
  5. 제4항에 있어서, 인슐린이 조성물의 성분인 조성물.
  6. 제5항에 있어서, 전상적인 글루코스 농도를 유지시키는데 필요한 인슐린의 양이 인슐린만을 투여하여 정상적인 글루코스 농도를 유지시키는데 필요한 양 미만인 조성물.
  7. 인슐린 의존성 진성 당뇨병에 걸리기 쉬운 포유동물에게 예방적 유효량의 라파마이신을 투여함을 특징으로하여, 포유동물의 인슐린 의존성 진성 당뇨병의 시작을 예방하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920005491A 1991-04-03 1992-04-02 당뇨병 치료용 조성물 KR100206054B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67970691A 1991-04-03 1991-04-03
US7/679,706 1991-04-03
US07/679,706 1991-04-03
US07/792,105 US5321009A (en) 1991-04-03 1991-11-14 Method of treating diabetes
US07/792,105 1991-11-14

Publications (2)

Publication Number Publication Date
KR920019347A true KR920019347A (ko) 1992-11-19
KR100206054B1 KR100206054B1 (ko) 1999-07-01

Family

ID=24728015

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920005491A KR100206054B1 (ko) 1991-04-03 1992-04-02 당뇨병 치료용 조성물

Country Status (3)

Country Link
US (1) US5321009A (ko)
KR (1) KR100206054B1 (ko)
TW (1) TW203554B (ko)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US8078407B1 (en) 1997-03-28 2011-12-13 Health Hero Network, Inc. System and method for identifying disease-influencing genes
US5956501A (en) * 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
US6968375B1 (en) 1997-03-28 2005-11-22 Health Hero Network, Inc. Networked system for interactive communication and remote monitoring of individuals
US20010011224A1 (en) 1995-06-07 2001-08-02 Stephen James Brown Modular microprocessor-based health monitoring system
US9215979B2 (en) 1992-11-17 2015-12-22 Robert Bosch Healthcare Systems, Inc. Multi-user remote health monitoring system
US5307263A (en) 1992-11-17 1994-04-26 Raya Systems, Inc. Modular microprocessor-based health monitoring system
US8078431B2 (en) 1992-11-17 2011-12-13 Health Hero Network, Inc. Home power management system
US7624028B1 (en) 1992-11-17 2009-11-24 Health Hero Network, Inc. Remote health monitoring and maintenance system
US8027809B2 (en) 1992-11-17 2011-09-27 Health Hero Network, Inc. Home power management system
US6330426B2 (en) 1994-05-23 2001-12-11 Stephen J. Brown System and method for remote education using a memory card
US5951300A (en) 1997-03-10 1999-09-14 Health Hero Network Online system and method for providing composite entertainment and health information
US5832448A (en) 1996-10-16 1998-11-03 Health Hero Network Multiple patient monitoring system for proactive health management
AU1766201A (en) 1992-11-17 2001-05-30 Health Hero Network, Inc. Method and system for improving adherence with a diet program or other medical regimen
US8095340B2 (en) 1992-11-17 2012-01-10 Health Hero Network, Inc. Home power management system
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
WO1996006847A1 (en) * 1994-08-31 1996-03-07 Pfizer Inc. Process for preparing demethylrapamycins
US5665387A (en) * 1994-09-01 1997-09-09 K.U. Leuven Research & Development Methods and compositions for primary and secondary prevention of autoimmune diabetes
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US7056935B2 (en) * 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
JP3089350B2 (ja) 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6032119A (en) 1997-01-16 2000-02-29 Health Hero Network, Inc. Personalized display of health information
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US20080004915A1 (en) 1998-09-25 2008-01-03 Brown Stephen J Dynamic modeling and scoring risk assessment
WO2001017953A1 (en) * 1999-09-08 2001-03-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
ATE319712T1 (de) 1999-12-21 2006-03-15 Mgi Gp Inc Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
CA2421485A1 (en) 2000-09-19 2002-03-28 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US6593362B2 (en) 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
WO2003018574A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
BR0211986A (pt) 2001-08-22 2004-09-28 Wyeth Corp 29-enóis de rapamicina
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
NZ537829A (en) * 2002-07-30 2006-09-29 Wyeth Corp Parenteral formulations containing a rapamycin hydroxyester
US20050070567A1 (en) * 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
EP1546369A4 (en) * 2002-08-12 2007-01-17 Univ Michigan DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
RU2326654C2 (ru) * 2002-09-17 2008-06-20 Уайт Пероральные композиции
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
CN1777424A (zh) * 2003-04-22 2006-05-24 惠氏公司 抗肿瘤联合药物
US7399276B1 (en) 2003-05-08 2008-07-15 Health Hero Network, Inc. Remote health monitoring system
US20070191259A1 (en) * 2003-08-22 2007-08-16 Johan Auwerx Inhibition of s6 kinaze activity for the treatment of insulin resistance
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
KR101276754B1 (ko) 2004-07-19 2013-06-19 바이오콘 리미티드 인슐린―올리고머 접합체，제형 및 이들의 용도
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
US20080207671A1 (en) * 2006-07-31 2008-08-28 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
WO2008033956A2 (en) 2006-09-13 2008-03-20 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080188461A1 (en) * 2007-02-01 2008-08-07 Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
EP2203181B1 (en) 2007-10-16 2018-02-14 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
CN102231969A (zh) * 2008-10-03 2011-11-02 万能医药公司 大环内酯化合物及其使用方法
EP2365802B1 (en) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
ES2685947T3 (es) 2009-04-10 2018-10-15 Haiyan Qi Agentes antienvejecimiento
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2906214A1 (en) 2012-10-12 2015-08-19 The Board of Regents of The University of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
EP2968281B1 (en) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
IT1133010B (it) * 1980-05-15 1986-07-09 Sigma Tau Ind Farmaceuti Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin

Also Published As

Publication number Publication date
US5321009A (en) 1994-06-14
TW203554B (ko) 1993-04-11
KR100206054B1 (ko) 1999-07-01

Similar Documents

Publication Publication Date Title
KR920019347A (ko) 당뇨병의 치료방법
EA200000041A1 (ru) Способ лечения диабета тиазолидиндионом и метформином
KR890011590A (ko) 안지오스타틴
CA2329004A1 (en) Combination of insulin sensitizer with anorectic for treating or preventing diabetes
AU2059695A (en) Gestodene-containing agent for transdermal administration
RU97104029A (ru) Лечение сахарного диабета типа ii агонистами амилина
RU2003100076A (ru) Противосудорожные производные, используемые для профилактики развития сахарного диабета и синдрома х
NO20000314L (no) Farmasøytiske sammensetninger som inneholder lysostafin alene eller i kombinasjon med et antibiotika for behandling av stafylokokkinfeksjoner
BR9811137A (pt) Processo para redução de hiperglicemia e processo para redução de hiperglicemia e estabilização do nìvel de glicose sérica, composição farmacêutica, e, uso de tripicolinato crÈmico sintético
KR880013555A (ko) 당뇨병의 치료방법
TR200000134T2 (tr) Tiazolidinedion, ensülin salgılatıcısı ve biguanid ile diabetin (şeker hastalığının) tedavisi.
BR9810444A (pt) Tratamento de diabete com rosiglitazona e insulina
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
KR920021144A (ko) 역류성 식도염을 치료하기위한 니자티딘의 용도
KR920000326A (ko) 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도
KR910016338A (ko) 클로스트리듐 디피실레 하리증 및 위막성 대장염의 예방 및 치료용 의약조성물
KR910019623A (ko) 상승병용을 이용한 안고혈압 치료
BR9810292A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase
KR910000130A (ko) 진경제
KR910019621A (ko) 상승병용을 이용한 안고혈압 치료
KR920017668A (ko) 암 전이 억제 또는 예방 방법 및 이를 위한 제제
BR9810186A (pt) Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade
EA200000141A1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
KR890011572A (ko) 정신 기능을 증진시키는 방법
NZ520829A (en) Diphenylethylene compounds for treating diabetes and related conditions

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Publication of correction
FPAY Annual fee payment

Payment date: 20050331

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee